The post WhiteBIT Coin Gains Momentum After Kraken Listing as Token Climbs to Top 11 by Market Cap appeared on BitcoinEthereumNews.com. Key highlights: WhiteBITThe post WhiteBIT Coin Gains Momentum After Kraken Listing as Token Climbs to Top 11 by Market Cap appeared on BitcoinEthereumNews.com. Key highlights: WhiteBIT

WhiteBIT Coin Gains Momentum After Kraken Listing as Token Climbs to Top 11 by Market Cap

For feedback or concerns regarding this content, please contact us at [email protected]

Key highlights:

  • WhiteBIT Coin began trading on Kraken with WBT/EUR and WBT/USD pairs, expanding global access to the exchange’s native token.
  • The token gained about 6.5% following the listing and now ranks as the 11th-largest cryptocurrency with a market cap around $10.7 billion.
  • WBT powers the WhiteBIT ecosystem by offering benefits such as fee discounts, staking rewards, and participation in launchpad projects.

Kraken listing broadens access to WhiteBIT’s ecosystem token

WhiteBIT Coin, the native token of the WhiteBIT cryptocurrency exchange, is now available for trading on the Kraken platform. The listing introduces WBT trading pairs against the euro and the U.S. dollar, opening access to the asset for a wider global audience.

Following the announcement, WBT recorded a price increase of roughly 6.5%, reflecting heightened market attention surrounding the listing. The token’s market capitalization has reached approximately $10.7 billion, placing it among the top 11 cryptocurrencies according to industry tracking platforms.

WhiteBIT Coin was launched in 2022 as a utility token designed to support activity across the WhiteBIT trading ecosystem. Within the platform, WBT provides users with several functional benefits. These include discounts on trading fees that can reach up to 100%, higher referral bonuses, and fee-free daily withdrawals.

“Listing WBT on Kraken represents a logical next step in the expansion of the WhiteBIT ecosystem,” said Volodymyr Nosov, founder and president of W Group. “It reflects the momentum we’ve built through ecosystem growth, strategic partnerships, and increasing institutional visibility.”

Ecosystem expansion and partnerships support WBT growth

Recent developments across the broader WhiteBIT ecosystem have contributed to the token’s growing visibility. The company has formed partnerships with several organizations, including an agreement with Italian football club Juventus that made WhiteBIT the team’s official sleeve and cryptocurrency exchange partner.

The exchange has also pursued geographic expansion. New operational initiatives have targeted markets in South America and the United States, while collaborations in the Middle East have focused on blockchain infrastructure and central bank digital currency (CBDC) initiatives.

Another sign of growing institutional interest is WBT’s inclusion in the S&P Crypto Indices, a benchmark that tracks selected digital assets across the market. Inclusion in such indices typically reflects factors such as liquidity, trading activity, and market relevance.

WhiteBIT itself has grown into one of Europe’s largest crypto exchanges by traffic. The platform currently offers more than 900 trading pairs and supports over 350 digital assets alongside eight fiat currencies. Since its founding in 2018, the exchange has expanded to serve tens of millions of users worldwide.

The bottom line

The addition of WhiteBIT Coin to Kraken represents a step toward wider market accessibility for the token. As exchange-native assets continue to gain attention in the crypto sector, listings on major platforms can play an important role in improving liquidity and expanding the potential user base for ecosystem tokens like WBT.

Source: https://coincodex.com/article/82666/whitebit-coin-gains-momentum-after-kraken-listing-as-token-climbs-to-top-11-by-market-cap/

Market Opportunity
WhiteBIT Token Logo
WhiteBIT Token Price(WBT)
$54.421
$54.421$54.421
-0.39%
USD
WhiteBIT Token (WBT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09